Biomarkers, Pathways, and Targeted Therapies®
How Test Reimbursement Decisions Are Made: A Leader of Medicare’s MolDX Program Discusses Evaluation Process
Despite the promise associated with biomarker-based tools as a means of helping to guide cancer diagnosis and treatment, there is a potential stumbling block: insurance reimbursement.
Most Popular Right Now
Precision Medicine in Oncology®
Precision Medicine—An Inevitable (Though Challenging) Goal!Andre Goy, MD, writes about implementing precision medicine, which requires a global effort from clinicians, insurance providers, government regulators, and the pharmaceutical industry.
Read more >>>